NCT06097663: A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) |
|
|
| Completed | 2 | 31 | Europe, Canada, US | MAS825, MAS825 Placebo, DFV890, DFV890 placebo | Novartis Pharmaceuticals | Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP) | 10/24 | 11/24 | | |
